Catalyst Biosciences, Inc.

DB:HGF2 Stock Report

Market Cap: €18.3m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Catalyst Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Nassim Usman

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage24.9%
CEO tenure8.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nassim Usman's remuneration changed compared to Catalyst Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$44m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

US$7m

Dec 31 2022US$2mUS$595k

-US$8m

Sep 30 2022n/an/a

US$12m

Jun 30 2022n/an/a

-US$8m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$1mUS$595k

-US$88m

Sep 30 2021n/an/a

-US$87m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$1mUS$574k

-US$56m

Sep 30 2020n/an/a

-US$51m

Jun 30 2020n/an/a

-US$48m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$1mUS$525k

-US$55m

Sep 30 2019n/an/a

-US$52m

Jun 30 2019n/an/a

-US$47m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$2mUS$481k

-US$30m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$23m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$2mUS$464k

-US$26m

Sep 30 2017n/an/a

-US$24m

Jun 30 2017n/an/a

-US$22m

Mar 31 2017n/an/a

-US$17m

Dec 31 2016US$570kUS$453k

-US$17m

Compensation vs Market: Nassim's total compensation ($USD2.39M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Nassim's compensation has increased whilst the company is unprofitable.

CEO

Nassim Usman (63 yo)

8.3yrs

Tenure

US$2,392,782

Compensation

Dr. Nassim Usman, Ph.D. serves as a Venture Partner at Morgenthaler Ventures. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also serv...

Board Members

NamePositionTenureCompensationOwnership
Nassim Usman
President8.3yrsUS$2.39mno data
Augustine Lawlor
Independent Chairman of the Board17.8yrsUS$91.00kno data
James Wells
Member of Scientific Advisory Boardno datano datano data
Shaun Coughlin
Member of Scientific Advisory Boardno datano datano data
Edwin Madison
Member of Scientific Advisory Board7.2yrsUS$695.83kno data
Thomas Eastling
Independent Directorless than a yearno datano data
Ying Luo
Independent Directorless than a yearno datano data
David Ginsburg
Member of Scientific Advisory Board14.7yrsno datano data
Robert Fletterick
Member of Scientific Advisory Board14.7yrsno datano data
Guy Salvesen
Member of Scientific Advisory Board14.7yrsno datano data
Andrea Hunt
Independent Director6.1yrsUS$50.00k0.074%
€ 13.6k

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: HGF2's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/01 08:30
End of Day Share Price 2023/10/30 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Catalyst Biosciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George ZavoicoB. Riley Securities, Inc.
Gbolahan Amusa BenzChardan Capital Markets, LLC
Kevin DeGeeterLadenburg Thalmann & Company